p16INK4a-TAT Polyclonal Antibody, Biotin, PeproTech®, Invitrogen™

Description

• AA Sequence of recombinant protein: EPAAGSSMEP SADWLATAAA RGRVEEVRAL LEAGALPNAP NSYGRRPIQV MMMGSARVAE LLLLHGAEPN CADPATLTRP VHDAAREGFL DTLVVLHRAG ARLDVRDAWG RLPVDLAEEL GHRDVARYLR AAAGGTRGSN HARIDAAEGP SDIPDGYGR KKRRQRRR
• Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human p16-INK4a-TAT
• Anti-Human p16-INK4a-TAT-specific antibody was purified by affinity chromatography and then biotinylated
• Sandwich ELISA: To detect Human p16-INK4a-TAT by sandwich ELISA (using 100 μL/well), a concentration of 0.25-1.0 μg/mL of this antibody is required
• This biotinylated polyclonal antibody,in conjunction with PeproTech Polyclonal Anti-Human p16-INK4a-TAT (500-P284) as a capture antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human p16-INK4a-TAT
• Western Blot: To detect Human p16-INK4a-TAT by Western Blot analysis, this antibody can be used at a concentration of 0.1-0.2 μg/mL.When used in conjunction with compatible development reagents, the detection limit for Recombinant Human p16-INK4a-TAT is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions
• 500-P284TBT-1MG will be provided as 2 x 500 μg p16-INK4a is a nuclear protein that regulates the cell cycle by inhibiting cyclin-dependent kinase-4 (CDK4) and CDK6
• p16-INK4a inhibits CDK activity by binding to the CDK molecules in a manner that interferes with their ability to interact with cyclin D
• This activity has the effect of suppressing tumor formation and growth, and of inducing replicative senescence in various normal cells, including stem cells
• The expression of p16-INK4a steadily increases with age, and tends to accumulate in stem cell compartments
• The deletion, rearrangement, or mutation of the p16-INK4a gene is frequently found in melanomas, as well as in certain other types of cancer
• p16-INK4a and other transcription factors have been introduced into cells by DNA transfection, viral infection, or microinjection
• Protein transduction using TAT fusion proteins represents an alternative methodology for introducing transcription factors and other nuclear proteins into primary, as well as transformed, cells.